Brazil's vivax malaria vaccine candidate cleared for human trials

A vaccine candidate against Plasmodium vivax malaria, developed by USP and CTVacinas/UFMG, has received regulatory approval to begin human trials. If successful, it would be the first vaccine against this malaria variety, which is prevalent in the Americas and Asia. The approval marks a significant step in malaria control, though efficacy and safety remain unproven.